Auriga CEO outlines plan to generate high-growth revenues

By E. Janene Geiss

Philadelphia, Sept. 14 - Auriga Laboratories, Inc. announced Thursday that chief executive officer Philip S. Pesin will send a letter to shareholders detailing the company's business model to generate high-growth revenues by capitalizing on multiple opportunities in the prescription drug marketplace.

"Auriga is a specialty pharmaceutical company committed to generating growth through a strategy designed to create both short-term cash flow and long-term value," Pesin wrote in the letter, which was detailed in a company news release.

Auriga's scientific and commercial teams have a strategy that allows the Norcross, Ga., pharmaceutical company to maintain a market presence by constantly measuring the effectiveness of its promotional efforts and taking a proactive approach through an aggressive patent filing strategy.

Auriga recently announced the acquisition of a license to market the Levall family of common cold remedy prescription drug products from Athlon Pharmaceuticals in a $20 million deal. Auriga said it intends to extend Levall's market exclusivity through the development of new drug formulations within the brand.

The chief executive said the company will focus on product acquisitions as a means to "achieve and maintain market exclusivity through forward-thinking regulatory and high-margin IP strategies that involve application of novel drug-delivery technologies and formulations."

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.